子宫肌瘤保留子宫干预后的再干预风险与生活质量结局:系统综述与Meta分析
该系统综述与Meta分析纳入85篇文章共17789名接受保留子宫治疗的子宫肌瘤女性,比较不同术式在12、36、60个月的再干预风险及生活质量。60个月再干预风险:子宫肌瘤剔除术12.2%,子宫动脉栓塞术14.4%,高强度聚焦超声53.9%,宫腔镜7%。所有术式症状均改善,高强度聚焦超声结局最不理想。
要点
- 60个月再干预风险:子宫肌瘤剔除术12.2%,子宫动脉栓塞术14.4%,高强度聚焦超声53.9%,宫腔镜7%。
- 其他术式在60个月时无可用研究数据。
- 所有保留子宫术式治疗后症状均改善,高强度聚焦超声结局最不理想。
核心结论
- 尽管研究人群存在显著异质性,本Meta分析为各种保留子宫干预措施的相对疗效提供了有价值的信息,适用于日常实践中的患者咨询。
- 本研究显示,尤其是针对最新保留子宫干预措施的长期数据亟需获取。
研究设计与样本
- 遵循PRISMA指南的系统综述与Meta分析,纳入85篇文章,共17789名接受保留子宫干预的子宫肌瘤女性。
- 分别对腹部入路术式(子宫肌瘤剔除术、子宫动脉栓塞术、动脉结扎术、高强度聚焦超声、腹腔镜射频消融术)和宫腔内肌瘤术式(宫腔镜入路,包括宫腔镜子宫肌瘤剔除术和宫腔镜射频消融术)进行两项独立分析。
主要发现
- 60个月再干预风险:子宫肌瘤剔除术12.2%(95%CI 5.2%-21.2%),子宫动脉栓塞术14.4%(95%CI 9.8%-19.6%),高强度聚焦超声53.9%(95%CI 47.2%-60.4%),宫腔镜7%(95%CI 4.8%-9.5%)。
- 其他治疗选项在60个月时无可用研究。
- 生活质量结局方面,所有术式治疗后症状均改善,高强度聚焦超声结局最不理想。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究人群存在显著异质性。
- 最新保留子宫干预措施的长期数据亟需获取。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare uterine-sparing treatment options for fibroids in terms of reintervention risk and quality of life. DESIGN: Systematic review and meta-analysis according to PRISMA guidelines. SETTING: Not applicable. PATIENT(S): Women with uterine fibroids undergoing a uterine-sparing intervention. INTERVENTIONS(S): Not applicable. MAIN OUTCOME MEASURE(S): 1) Reintervention risk after uterine-sparing treatment for fibroids after 12, 36, and 60 months; and 2) quality of life outcomes, based on validated questionnaires. Two separate analyses were performed for the procedures that used an abdominal approach (myomectomy, uterine artery embolization [UAE], artery ligation, high-intensity focused ultrasound [HIFU], laparoscopic radiofrequency ablation [RFA]) and for the procedures managing intracavitary fibroids (hysteroscopic approach, including hysteroscopic myomectomy and hysteroscopic RFA). RESULT(S): There were 85 articles included for analysis, representing 17,789 women. Stratified by treatment options, reintervention risk after 60 months was 12.2% (95% confidence interval [CI] 5.2%-21.2%) for myomectomy, 14.4% (95% CI 9.8%-19.6%) for UAE, 53.9% (95% CI 47.2%-60.4%) for HIFU, and 7% (95% CI 4.8%-9.5%) for hysteroscopy. For the other treatment options, no studies were available at 60 months. For quality of life outcomes, symptoms improved after treatment for all options. The HIFU procedure had the least favorable outcomes. CONCLUSION(S): Despite the substantial heterogeneity of the study population, this meta-analysis provides valuable information on relative treatment efficacy of various uterine-sparing interventions for fibroids, which is relevant when counseling patients in daily practice. Furthermore, this study demonstrates that long-term data, particularly for the newest uterine-sparing interventions, are urgently needed.
引用
- Sandberg EM, Tummers FHMP, Cohen SL, et al. Reintervention risk and quality of life outcomes after uterine-sparing interventions for fibroids: a systematic review and meta-analysis. Fertil Steril. 2018. PMID: 29653718. doi:10.1016/j.fertnstert.2017.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。